CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced the appointment of Dr. Liu Yongjun as its Group CEO and Global R&D President. Dr. Liu will be responsible for leading the company’s research and development, pipeline strategy, and global business development initiatives.
Dr. Liu brings over 30 years of experience in the biopharmaceutical industry, with a distinguished track record in immunology, oncology, and translational medicine. He has held senior R&D positions at notable companies including Innovent Bio, Sanofi, and AstraZeneca’s MedImmune.
Dr. Liu’s academic credentials include a Bachelor of Medicine degree from Norman Bethune Medical University in China and a PhD in Immunology from the University of Birmingham in the United Kingdom. His research has been widely recognized, with over 260 publications in prestigious academic journals such as Nature and Science. His work has been cited more than 94,000 times, significantly contributing to the advancement of immunology and oncology through key drug targets like thymic stromal lymphopoietin (TSLP), OX40 (CD134), and plasma cell-like dendritic cells (pDCs).- Flcube.com
